Oral Zinc Supplementations as Adjuvant Therapy in Treatment of Anemia in Maintenance Hemodialysis Patients with Hypozencemia

AL Nahal, AL Sayed; Shehata, Marwan A.; Fikry, Abeer A.; Mahmoud, Medhat Ibrahim

doi:10.21608/zumj.2023.244431.2988

	Oral Zinc Supplementations as Adjuvant Therapy in Treatment of Anemia in Maintenance Hemodialysis Patients with Hypozencemia
Zagazig University Medical Journal
Articles in Press, Accepted Manuscript, Available Online from 20 November 2023
Document Type: Original Article
DOI: 10.21608/zumj.2023.244431.2988
View on SCiNiTO
Authors
AL Sayed AL Nahal ¹; Marwan A. Shehata ¹; Abeer A. Fikry ²; Medhat Ibrahim Mahmoud ³
¹Internal Medicine, Department, Faculty of Medicine, Zagazig University, Egypt.
²Clinical pathology, Department, Faculty of Medicine, Zagazig University, Egypt.
³1Internal Medicine, Department, Faculty of Medicine, Zagazig University, Egypt.
Abstract
Background: Regular hemodialysis patients are at an increased risk of developing anemia due to multiple causes. Some research has suggested that hypozencemia may contribute to anemia in regular hemodialysis patients. Objective: Evaluation of the effect of zinc supplementation in the treatment of anemia in regular hemodialysis patients with hypozencemia. Patients and methods: An intervention study(open labeled) that was conducted on 54 anaemic regular hemodialysis patients with hypozencemia was divided into 2 groups: group I (zinc supplementation group), which included 27 cases, and group II (control group), which included 27 controls. All patients were followed up for 6 months. Results: post-zinc treatment, group 1 showed a statistically significant increase in serum zinc level, whereas group 2 showed no statistically significant difference in serum zinc level (p<0.05 ). Serum iron and transferrin saturation showed no statistically significant difference before and after follow-up in both groups(p>0.05 ). haemoglobin level showed a statistically significant increase between baseline and six months. meanwhile, after 3 to 6 months, there was a statistically significant increase in haemoglobin in group 1 compared to group 2(p<0.05 ). There was no statistically significant difference between the two groups regarding hemoglobin , serum zinc, C-reactive protein, ferritin, and erythropoietin resistance index before the start of the study(p>0.05 ).. Erythropiotine dosage showed a statistically significant decrease from baseline to 6 months in group I(p<0.05 ). Conclusion: Oral zinc supplementation, when used as an adjuvant therapy, may have a positive impact on haemoglobin levels and erythropiotine, utilisation in hemodialysis patients with hypozencemia.
Keywords
Hypozencemia; Hemodialysis Patients; Anemia; Zinc Supplementation


Statistics Article View: 99